Compare Regeneron Pharmaceuticals Inc (REGN) vs SK Hynix (SKHY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

SKHY trades at $185.55, up 4.83% today, with strong fundamental performance including 85.62% net income margin and consistent earnings beats. The stock shows neutral technical signals near pivot point $186, with support at $183 and resistance at $189. Recent news highlights SKHY's leadership in AI memory chips with 50% HBM market share and strong demand from AI infrastructure buildout.

Outlook remains positive with 100% analyst buy ratings and $248 consensus price target representing 34% upside. Key risks include memory cycle volatility and competitive pressures, but strong HBM positioning and expanding AI partnerships provide growth catalysts. Revenue growth accelerated to 85.61% profit margin in 2026 trends.